<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67897">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02221947</url>
  </required_header>
  <id_info>
    <org_study_id>NTRP101-201</org_study_id>
    <nct_id>NCT02221947</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Preliminary Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bryostatin 1 in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurotrope Bioscience, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Blanchette Rockefeller Neurosciences Insitute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neurotrope Bioscience, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to evaluate the safety, tolerability and potential effectiveness of
      a new investigational drug, bryostatin 1, in patients with Alzheimer's disease (AD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single center, randomized, double-blind, placebo-controlled, parallel groups
      trial in patients with AD. Each subject enrolled in the trial will be randomized to receive
      a single IV dose of 0 (placebo) or 25 μg/m2 bryostatin. A total of 15 subjects (5 in the
      placebo arm and 10 in the treatment arm) will be enrolled in the study. The study consists
      of screening evaluations and on study evaluations divided into two segments, an inpatient
      segment and an outpatient segment. The four-day inpatient segment will consist of baseline
      evaluations and a 1-hour IV infusion of study drug followed by evaluations at multiple
      evaluations over the first 72 hrs post dose. During the outpatient segment, patients will be
      followed for AEs and have a final evaluation at 2 weeks post dose and a 4-week telephone
      safety follow up. Evaluations will include safety, efficacy, pharmacokinetics, and
      pharmacodynamics as assessed by PKC activity
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Part 2 of study replaced by NTRP-101-202, assessing 3 doses of bryostatin.
  </why_stopped>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Within 2 weeks of study drug dosing</time_frame>
    <description>Evaluate the safety and tolerability of bryostatin 1 (hereinafter referred to as bryostatin) in patients with Alzheimer's Disease (AD) following a single intravenous (IV) dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary Efficacy of a Single Dose of Bryostatin in the Treatment of Patients With AD</measure>
    <time_frame>Within 2 weeks of study drug dosing</time_frame>
    <description>HVLT-R (Hopkins Verbal Learning Test-Revised™ (HVLT-R™) delayed free recall, HVLT-R delayed cued recall, HVLT-R delayed recognition recall, RBANS figure recall at 48 hour post start of study drug infusion. HVLT-R delayed free recall, HVLT-R delayed cued recall, HVLT-R delayed recognition recall, RBANS figure recall at 24 hours and 2 weeks post start of study drug infusion HVLT-R delayed free recall, HVLT-R delayed cued recall, HVLT-R delayed recognition recall of stimuli presented 48 hours post study drug infusion, as assessed 72 hours post start of study drug infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Efficacy of a Single Dose of Bryostatin in the Treatment of Patients With AD</measure>
    <time_frame>within 2 weeks of study drug dosing</time_frame>
    <description>Digit Symbol Coding at 3, 24 and 48 hours and 2 weeks post start of study drug infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Efficacy of a Single Dose of Bryostatin in the Treatment of Patients With AD</measure>
    <time_frame>within 2 weeks of study drug dosing</time_frame>
    <description>CDR, Clinical Dementia Rating Sum of Boxes (CDR-SB) and individual items at 2 weeks post start of study drug infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Efficacy of a Single Dose of Bryostatin in the Treatment of Patients With AD</measure>
    <time_frame>within 2 weeks of study drug dosing</time_frame>
    <description>MMSE-2 (Mini-Mental® State Examination, 2nd Edition) at 3 and 72 hours, and 2 weeks post start of study drug infusion</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Parameters (Cmax, Tmax, AUClast, AUCinf, λz, T1/2, CL, Vz) of Bryostatin.</measure>
    <time_frame>Within 2 weeks of study drug dosing</time_frame>
    <description>Preliminary evaluation of pharmacokinetics, pharmacodynamics and to correlate the changes in protein kinase C (PKC) with plasma levels of bryostatin and with improvement in cognitive function in patients with AD. PBMC PKC activity at baseline (within 30 minutes prior to study drug infusion), during the infusion (30 and 60 min post the start of study drug infusion), and at 80 min, 2, 3, 6, 24, 48, 72 hrs and 2 weeks post start of study drug infusion. Blood will be drawn at baseline (within 30 minutes prior to study drug infusion), during the infusion (15, 30, and 60 min post start of study drug infusion), and at 80 min, 2, 3, 6, 12, 24, 36, 48, 72 hrs and 2 weeks post start of study drug infusion to assess pharmacokinetic parameters (Cmax, Tmax, AUClast, AUCinf, λz, T1/2, CL, Vz) of bryostatin.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Bryostatin 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose of 25 μg/m2 bryostatin, intravenous infusion over 1 hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose of placebo, intravenous infusion over 1 hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bryostatin 1</intervention_name>
    <description>25 μg/m2 bryostatin 1, single dose via intravenous infusion over 1 hour.</description>
    <arm_group_label>Bryostatin 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, single dose via intravenous infusion over 1 hour.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age 50 - 85 yrs. Females are non-childbearing potential

          -  Patient must have a cognitive deficit present for at least 1 year and meet diagnostic
             criteria for probable Alzheimer's Disease Dementia by NIA-AA criteria or prodromal
             Alzheimer's Disease

          -  Mini Mental State Exam score of 16-26

          -  Ability to walk, at least with an assistive device

          -  Vision and hearing sufficient to comply with testing

          -  Normal cognitive and social functioning prior to onset of dementia, with evidence of
             progressive symptoms from patient or informant

          -  Consistent caregiver to accompany patient to visits

          -  Sufficient basic education to be able to complete the cognitive assessments

          -  Living outside an institution

        Exclusion Criteria:

          -  Dementia due to any condition other than AD, including vascular dementia

          -  Significant neuroimaging abnormalities, previously known or discovered on screening
             MRI scan,

          -  Evidence of clinically significant unstable cardiovascular, renal, hepatic,
             gastrointestinal, neurological, or metabolic disease within the past 6 months

          -  Use of any drug within 14 days prior to randomization unless the dose of the drug and
             the condition being treated have been stable for at least 30 days and are expected to
             remain stable during the study

          -  Use of tobacco products or nicotine-containing products within 3 months before Day 1

          -  Use of high dose vitamin E, or valproic acid

          -  Any medical or psychiatric condition that may require medication or surgical
             treatment during the study

          -  Life expectancy less than 6 months

          -  Use of an investigational drug within 2 months prior to the screening visit

          -  Clinically significant neurological disease other than AD

          -  Major depression, alcohol or drug dependence or suicidality

          -  Psychotic episodes requiring hospitalization or antipsychotic therapy for more than 2
             weeks within the past 10 years, not linked to AD

          -  Agitation sufficient to preclude participation in this trial

          -  Epilepsy or anti-epileptic drug therapy

          -  Abnormal laboratory tests that might point to another etiology for dementia;

          -  Acute or poorly controlled medical illness

          -  Likelihood, according to clinical judgment, of being transferred to a nursing home
             within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hakop Gevorkyan, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Clinical Trials Medical Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Clinical Trials Medical Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 21, 2016</lastchanged_date>
  <firstreceived_date>July 2, 2014</firstreceived_date>
  <firstreceived_results_date>March 21, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's</keyword>
  <keyword>bryostatin</keyword>
  <keyword>PKC epsilon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bryostatin 1</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bryostatin 1</title>
          <description>single dose of 25 μg/m2 bryostatin, intravenous infusion over 1 hour
Bryostatin 1: 25 μg/m2 bryostatin 1, single dose via intravenous infusion over 1 hour.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>single dose of placebo, intravenous infusion over 1 hour
Placebo: Placebo, single dose via intravenous infusion over 1 hour.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bryostatin 1</title>
          <description>single dose of 25 μg/m2 bryostatin, intravenous infusion over 1 hour
Bryostatin 1: 25 μg/m2 bryostatin 1, single dose via intravenous infusion over 1 hour.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>single dose of placebo, intravenous infusion over 1 hour
Placebo: Placebo, single dose via intravenous infusion over 1 hour.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.5" spread="8.04"/>
                    <measurement group_id="B2" value="70.7" spread="7.23"/>
                    <measurement group_id="B3" value="71.9" spread="7.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
        <description>Evaluate the safety and tolerability of bryostatin 1 (hereinafter referred to as bryostatin) in patients with Alzheimer's Disease (AD) following a single intravenous (IV) dose.</description>
        <time_frame>Within 2 weeks of study drug dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bryostatin 1</title>
            <description>single dose of 25 μg/m2 bryostatin, intravenous infusion over 1 hour
Bryostatin 1: 25 μg/m2 bryostatin 1, single dose via intravenous infusion over 1 hour.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>single dose of placebo, intravenous infusion over 1 hour
Placebo: Placebo, single dose via intravenous infusion over 1 hour.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
          <description>Evaluate the safety and tolerability of bryostatin 1 (hereinafter referred to as bryostatin) in patients with Alzheimer's Disease (AD) following a single intravenous (IV) dose.</description>
          <units>event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Papular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preliminary Efficacy of a Single Dose of Bryostatin in the Treatment of Patients With AD</title>
        <description>HVLT-R (Hopkins Verbal Learning Test–Revised™ (HVLT-R™) delayed free recall, HVLT-R delayed cued recall, HVLT-R delayed recognition recall, RBANS figure recall at 48 hour post start of study drug infusion. HVLT-R delayed free recall, HVLT-R delayed cued recall, HVLT-R delayed recognition recall, RBANS figure recall at 24 hours and 2 weeks post start of study drug infusion HVLT-R delayed free recall, HVLT-R delayed cued recall, HVLT-R delayed recognition recall of stimuli presented 48 hours post study drug infusion, as assessed 72 hours post start of study drug infusion.</description>
        <time_frame>Within 2 weeks of study drug dosing</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preliminary Efficacy of a Single Dose of Bryostatin in the Treatment of Patients With AD</title>
        <description>Digit Symbol Coding at 3, 24 and 48 hours and 2 weeks post start of study drug infusion</description>
        <time_frame>within 2 weeks of study drug dosing</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preliminary Efficacy of a Single Dose of Bryostatin in the Treatment of Patients With AD</title>
        <description>CDR, Clinical Dementia Rating Sum of Boxes (CDR-SB) and individual items at 2 weeks post start of study drug infusion</description>
        <time_frame>within 2 weeks of study drug dosing</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preliminary Efficacy of a Single Dose of Bryostatin in the Treatment of Patients With AD</title>
        <description>MMSE-2 (Mini-Mental® State Examination, 2nd Edition) at 3 and 72 hours, and 2 weeks post start of study drug infusion</description>
        <time_frame>within 2 weeks of study drug dosing</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacokinetic Parameters (Cmax, Tmax, AUClast, AUCinf, λz, T1/2, CL, Vz) of Bryostatin.</title>
        <description>Preliminary evaluation of pharmacokinetics, pharmacodynamics and to correlate the changes in protein kinase C (PKC) with plasma levels of bryostatin and with improvement in cognitive function in patients with AD. PBMC PKC activity at baseline (within 30 minutes prior to study drug infusion), during the infusion (30 and 60 min post the start of study drug infusion), and at 80 min, 2, 3, 6, 24, 48, 72 hrs and 2 weeks post start of study drug infusion. Blood will be drawn at baseline (within 30 minutes prior to study drug infusion), during the infusion (15, 30, and 60 min post start of study drug infusion), and at 80 min, 2, 3, 6, 12, 24, 36, 48, 72 hrs and 2 weeks post start of study drug infusion to assess pharmacokinetic parameters (Cmax, Tmax, AUClast, AUCinf, λz, T1/2, CL, Vz) of bryostatin.</description>
        <time_frame>Within 2 weeks of study drug dosing</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bryostatin 1</title>
          <description>single dose of 25 μg/m2 bryostatin, intravenous infusion over 1 hour
Bryostatin 1: 25 μg/m2 bryostatin 1, single dose via intravenous infusion over 1 hour.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>single dose of placebo, intravenous infusion over 1 hour
Placebo: Placebo, single dose via intravenous infusion over 1 hour.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash Papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI cannot disclose trial results without permission from sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Regulatory Affairs</name_or_title>
      <organization>Neurotrope BioScience, Inc</organization>
      <phone>973-826-5109</phone>
      <email>dcrockford@neurotropebioscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
